<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217892</url>
  </required_header>
  <id_info>
    <org_study_id>D1691C00003</org_study_id>
    <nct_id>NCT01217892</nct_id>
  </id_info>
  <brief_title>Evaluation of Dapagliflozin Taken Twice-daily</brief_title>
  <official_title>A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5
      mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is
      beneficial in diabetes treatment, and if so, how it compares to treatment with metformin
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in HbA1c Levels</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Percent Change in Body Weight</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>To compare the percent change from baseline in body weight achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID, and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 1 week of double-blind treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HbA1c&lt;7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>To compare the adjusted proportions controlling for baseline HbA1c [acc. to Zhang, Tsiatis &amp; Davidian and Davidian, Tsiatis, Zhang &amp; Lu] of participants with HbA1c &lt;7.0% achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment, in patients who had HbA1c ≥7.0% at baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 2.5 mg twice-daily plus open-label metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 5.0 mg twice-daily plus open-label metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg once-daily plus open-label metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus open-label metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>2.5 mg tablet, taken orally, twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>5 mg tablet taken orally, twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>10 mg tablet taken orally, once daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>&gt;/= 1500 mg total daily dose, tablets taken orally, twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosis of T2DM

          -  Current antihyperglycaemic treatment with metformin immediate release formulation
             monotherapy &gt;/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment.
             Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.

          -  HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and
             Enrolment Visit 1.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of
             the Young (MODY) or secondary causes of diabetes mellitus

          -  History of diabetic ketoacidosis

          -  Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria,
             polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment

          -  FPG &gt;270 mg/dL (&gt;15.0 mmol/L)

          -  BMI &gt;45 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamik Parikh</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asslar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Biberach A.d. Riss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dippoldiswalde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falkensee</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meissen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wahlstedt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Csongrad</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyongyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mako</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TAT</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namestovo</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prievidza</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruzomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verulam</city>
        <state>Kwa Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umkomaas</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chur</city>
        <state>Graubunden</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geneva 14</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kreuzlingen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rorschach</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrov'sk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vynnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=296&amp;filename=CSR-D1691C00003.pdf</url>
    <description>CSR-D1691C00003.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=296&amp;filename=D1691C00003_Clinical_Study_Protocol_Redacted_10Jun2014.pdf</url>
    <description>D1691C00003_Clinical_Study_Protocol_Redacted</description>
  </link>
  <reference>
    <citation>Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2015 Jan;17(1):42-51. doi: 10.1111/dom.12387. Epub 2014 Oct 16.</citation>
    <PMID>25200570</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <results_first_submitted>January 21, 2013</results_first_submitted>
  <results_first_submitted_qc>October 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2013</results_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>metformin treated</keyword>
  <keyword>inadequate control</keyword>
  <keyword>metformin treatment alone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant enrolled: 5 November 2010. Last participant last visit for the 16-week period: 25 August 2011. 520 participants were enrolled, and 400 were randomized in 53 study centers in Europe and South Africa. Subjects with T2DM who showed inadequate glycemic control on metformin therapy alone.</recruitment_details>
      <pre_assignment_details>During a placebo lead-in period, participants were counselled on dietary and life-style modifications. Subjects eligible for the study were stratified according to their baseline HbA1c.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
          <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 5mg BID Plus Metformin</title>
          <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="P3">
          <title>Dapagliflozin 10mg OD Plus Metformin</title>
          <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="P4">
          <title>Placebo Plus Metformin</title>
          <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lab value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
          <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 5mg BID Plus Metformin</title>
          <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="B3">
          <title>Dapagliflozin 10mg OD Plus Metformin</title>
          <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="B4">
          <title>Placebo Plus Metformin</title>
          <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="9.01"/>
                    <measurement group_id="B2" value="55.3" spread="9.34"/>
                    <measurement group_id="B3" value="58.5" spread="9.78"/>
                    <measurement group_id="B4" value="58.5" spread="9.40"/>
                    <measurement group_id="B5" value="57.7" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>Percent [%]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.77" spread="0.747"/>
                    <measurement group_id="B2" value="7.78" spread="0.762"/>
                    <measurement group_id="B3" value="7.71" spread="0.709"/>
                    <measurement group_id="B4" value="7.94" spread="0.848"/>
                    <measurement group_id="B5" value="7.80" spread="0.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153.3" spread="33.27"/>
                    <measurement group_id="B2" value="155.3" spread="31.92"/>
                    <measurement group_id="B3" value="155.3" spread="36.26"/>
                    <measurement group_id="B4" value="157.8" spread="35.93"/>
                    <measurement group_id="B5" value="155.4" spread="34.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.49" spread="18.632"/>
                    <measurement group_id="B2" value="93.62" spread="16.641"/>
                    <measurement group_id="B3" value="90.58" spread="15.929"/>
                    <measurement group_id="B4" value="88.82" spread="15.327"/>
                    <measurement group_id="B5" value="91.37" spread="16.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in HbA1c Levels</title>
        <description>To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
            <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg BID Plus Metformin</title>
            <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg OD Plus Metformin</title>
            <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Metformin</title>
            <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in HbA1c Levels</title>
          <description>To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.0594" lower_limit="-0.63" upper_limit="-0.40"/>
                    <measurement group_id="O2" value="-0.65" spread="0.0600" lower_limit="-0.77" upper_limit="-0.53"/>
                    <measurement group_id="O3" value="-0.59" spread="0.0598" lower_limit="-0.70" upper_limit="-0.47"/>
                    <measurement group_id="O4" value="-0.30" spread="0.0593" lower_limit="-0.42" upper_limit="-0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05 using Hochberg's method to control the overall Type I error across hypotheses in the two Dapagliflozin BID groups, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0106</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided) applying Hochberg's method across the two Dapagliflozin BID groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group as effect (all treatment groups included) and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0840</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05 using Hochberg's method to control the overall Type I error across hypotheses in the two Dapagliflozin BID groups, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided) applying Hochberg's method across the two Dapagliflozin BID groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group as effect (all treatment groups included) and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0843</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Percent Change in Body Weight</title>
        <description>To compare the percent change from baseline in body weight achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID, and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
            <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg BID Plus Metformin</title>
            <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg OD Plus Metformin</title>
            <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Metformin</title>
            <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Percent Change in Body Weight</title>
          <description>To compare the percent change from baseline in body weight achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID, and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.3099"/>
                    <measurement group_id="O2" value="-3.20" spread="0.3125"/>
                    <measurement group_id="O3" value="-2.76" spread="0.3086"/>
                    <measurement group_id="O4" value="-1.04" spread="0.3105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3630</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3636</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 1</title>
        <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 1 week of double-blind treatment.</description>
        <time_frame>Baseline to Week 1</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 1 values</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
            <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg BID Plus Metformin</title>
            <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg OD Plus Metformin</title>
            <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Metformin</title>
            <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 1</title>
          <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 1 week of double-blind treatment.</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 1 values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="2.657"/>
                    <measurement group_id="O2" value="-14.7" spread="2.672"/>
                    <measurement group_id="O3" value="-15.5" spread="2.634"/>
                    <measurement group_id="O4" value="2.0" spread="2.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.7</ci_lower_limit>
            <ci_upper_limit>-9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.7</ci_lower_limit>
            <ci_upper_limit>-10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16</title>
        <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
            <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg BID Plus Metformin</title>
            <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg OD Plus Metformin</title>
            <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Metformin</title>
            <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16</title>
          <description>To compare the change from baseline in fasting plasma glucose (FPG) achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment.</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="2.738"/>
                    <measurement group_id="O2" value="-25.6" spread="2.759"/>
                    <measurement group_id="O3" value="-20.4" spread="2.720"/>
                    <measurement group_id="O4" value="-10.4" spread="2.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.05, two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group (all treatment groups included) and stratum (HbA1c &lt;7.0% vs &gt;=7.0% at randomization) as effect and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.4</ci_lower_limit>
            <ci_upper_limit>-9.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HbA1c&lt;7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.</title>
        <description>To compare the adjusted proportions controlling for baseline HbA1c [acc. to Zhang, Tsiatis &amp; Davidian and Davidian, Tsiatis, Zhang &amp; Lu] of participants with HbA1c &lt;7.0% achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment, in patients who had HbA1c ≥7.0% at baseline.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
            <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg BID Plus Metformin</title>
            <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg OD Plus Metformin</title>
            <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Metformin</title>
            <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HbA1c&lt;7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.</title>
          <description>To compare the adjusted proportions controlling for baseline HbA1c [acc. to Zhang, Tsiatis &amp; Davidian and Davidian, Tsiatis, Zhang &amp; Lu] of participants with HbA1c &lt;7.0% achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metformin after 16 weeks of double-blind treatment, in patients who had HbA1c ≥7.0% at baseline.</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) values</population>
          <units>Percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="24.6" upper_limit="42.5"/>
                    <measurement group_id="O2" value="38.2" lower_limit="29.1" upper_limit="47.3"/>
                    <measurement group_id="O3" value="28.1" lower_limit="19.0" upper_limit="37.1"/>
                    <measurement group_id="O4" value="21.4" lower_limit="13.2" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0455</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Methodology of Zhang, Tsiatis &amp; Davidian and Davidian, Tsiatis, Zhang &amp; Lu, with adjustment for baseline value.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.097</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>24.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <p_value_desc>significant at alpha=0.05 (2-sided). Key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group for treatment groups tested significantly different from placebo for the primary endpoint.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Methodology of Zhang, Tsiatis &amp; Davidian and Davidian, Tsiatis, Zhang &amp; Lu, with adjustment for baseline value.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.153</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>28.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 16 weeks double-blind treatment period plus 4 days / 30 days or up to follow-up visit if earlier.</time_frame>
      <desc>Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin 2.5mg BID Plus Metformin</title>
          <description>Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 5mg BID Plus Metformin</title>
          <description>Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="E3">
          <title>Dapagliflozin 10mg OD Plus Metformin</title>
          <description>Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
        <group group_id="E4">
          <title>Placebo Plus Metformin</title>
          <description>Placebo plus Metformin, oral, twice daily, &gt;=1500mg total daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For participants who did not complete 16 weeks LOCF (last observation carried forward) was used.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eva Johnsson</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

